HIF-1 signaling in drug resistance to chemotherapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Hypoxia-inducible factor 1 (HIF-1) signaling is frequently activated in human cancers, driven by tumor hypoxia and epigenetic factors.
• HIF-1 activation promotes cancer cell survival and therapeutic resistance by inhibiting apoptosis and senescence, and enhancing drug efflux and metabolism.

Purpose of the Study:

• To review the role of HIF-1 signaling in mediating therapeutic resistance across various human cancers.
• To discuss current strategies and ongoing efforts in developing HIF-1 inhibitors as a novel anti-cancer therapeutic approach.

Main Methods:

• Review of preclinical and clinical studies investigating HIF-1 signaling in cancer.
• Analysis of diverse mechanisms for inhibiting HIF-1 activity, including targeting HIF-1α protein levels, transcription, and complex formation.

Main Results:

• HIF-1 plays a critical role in promoting physiological changes that contribute to chemoresistance.
• Multiple agents targeting HIF-1 have shown efficacy in preclinical and clinical settings, contributing to anti-tumor effects.

Conclusions:

• Targeting HIF-1 is a viable strategy to enhance current cancer therapies and overcome drug resistance.
• Further development of HIF-1 inhibitors holds significant promise for improving cancer treatment outcomes.